{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:22:56Z","timestamp":1790623376016,"version":"4.1.0"},"reference-count":23,"publisher":"American Association for Cancer Research (AACR)","issue":"22","funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["1R01 DE025340"],"award-info":[{"award-number":["1R01 DE025340"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,11,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Oral tongue squamous cell carcinoma (OTSCC) is the most common oral cavity tumor. In this study, we examined the basis for the activity of programmed cell death protein (PD-1)-based immune checkpoint therapy that is being explored widely in head and neck cancers. Using multispectral imaging, we systematically investigated the OTSCC tumor microenvironment (TME) by evaluating the frequency of PD-1 expression in CD8+, CD4+, and FoxP3+ tumor-infiltrating lymphocytes (TIL). We also defined the cellular sources of PD-1 ligand (PD-L1) to evaluate the utility of PD-1:PD-L1 blocking antibody therapy in this patient population. PD-L1 was expressed in 79% of the OTSCC specimens examined within the TME. Expression of PD-L1 was associated with moderate to high levels of CD4+ and CD8+ TILs. We found that CD4+ TILs were present in equal or greater frequencies than CD8+ TILs in 94% of OTSCC and that CD4+FOXP3neg TILs were colocalized with PD-1\/PD-L1\/CD68 more frequently than CD8+ TILs. Both CD4+PD1+ and CD8+PD1+ TILs were anergic in the setting of PD-L1 expression. Overall, our results highlight the importance of CD4+ TILs as pivotal regulators of PD-L1 levels and in determining the responsiveness of OTSCC to PD1-based immune checkpoint therapy. Cancer Res; 77(22); 6365\u201374. \u00a92017 AACR.<\/jats:p>","DOI":"10.1158\/0008-5472.can-16-3453","type":"journal-article","created":{"date-parts":[[2017,9,25]],"date-time":"2017-09-25T20:25:37Z","timestamp":1506371137000},"page":"6365-6374","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":89,"title":["PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4+ TILs in the Presence of PD-L1+ TAMs"],"prefix":"10.1158","volume":"77","author":[{"given":"Austin K.","family":"Mattox","sequence":"first","affiliation":[{"name":"1Department of Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jina","family":"Lee","sequence":"additional","affiliation":[{"name":"2Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Westra","sequence":"additional","affiliation":[{"name":"3Department of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Pierce","sequence":"additional","affiliation":[{"name":"4Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Ghossein","sequence":"additional","affiliation":[{"name":"5Department of Pathology Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Faquin","sequence":"additional","affiliation":[{"name":"6Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Diefenbach","sequence":"additional","affiliation":[{"name":"7Ragon Institute of MGH, MIT, and Harvard, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc G.","family":"Morris","sequence":"additional","affiliation":[{"name":"8Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derrick T.","family":"Lin","sequence":"additional","affiliation":[{"name":"9Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori J.","family":"Wirth","sequence":"additional","affiliation":[{"name":"10Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armida","family":"Lefranc-Torres","sequence":"additional","affiliation":[{"name":"9Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichi","family":"Ishida","sequence":"additional","affiliation":[{"name":"2Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts."},{"name":"11Department of Otolaryngology-Head and Neck Surgery, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick D.","family":"Chakravarty","sequence":"additional","affiliation":[{"name":"12University of Aberdeen, School of Medicine and Dentistry, Scotland, AB25 2ZD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Johnson","sequence":"additional","affiliation":[{"name":"13Harvard University, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang C.","family":"Zeng","sequence":"additional","affiliation":[{"name":"14Vaccine and Immunotherapy Center, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huabiao","family":"Chen","sequence":"additional","affiliation":[{"name":"14Vaccine and Immunotherapy Center, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Poznansky","sequence":"additional","affiliation":[{"name":"14Vaccine and Immunotherapy Center, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil M.","family":"Iyengar","sequence":"additional","affiliation":[{"name":"15Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara I.","family":"Pai","sequence":"additional","affiliation":[{"name":"2Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2017,11,14]]},"reference":[{"key":"2022061706052377800_bib1","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.oraloncology.2010.06.006","article-title":"Prognostic evaluation of oral tongue cancer: means, markers and perspectives (I)","volume":"46","author":"Bello","year":"2010","journal-title":"Oral Oncol"},{"key":"2022061706052377800_bib2","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1200\/JCO.2010.31.7883","article-title":"Increasing incidence of oral tongue squamous cell carcinoma in young white women, age 18 to 44 years","volume":"29","author":"Patel","year":"2011","journal-title":"J Clin Oncol"},{"key":"2022061706052377800_bib3","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1177\/000348941212100606","article-title":"Long-term quality of life in young adults treated for oral cavity squamous cell cancer","volume":"121","author":"Thomas","year":"2012","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"2022061706052377800_bib4","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1054\/bjom.2001.0652","article-title":"Functional status of patients with oral cancer and its relation to style of coping, social support and psychological status","volume":"39","author":"Hassanein","year":"2001","journal-title":"Br J Oral Maxillofac Surg"},{"key":"2022061706052377800_bib5","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1177\/1060028015586218","article-title":"Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology","volume":"49","author":"Barbee","year":"2015","journal-title":"Ann Pharmacother"},{"key":"2022061706052377800_bib6","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S1470-2045(16)30066-3","article-title":"Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial","volume":"17","author":"Seiwert","year":"2016","journal-title":"Lancet Oncol"},{"key":"2022061706052377800_bib7","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"2022061706052377800_bib8","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J Clin Oncol"},{"key":"2022061706052377800_bib9","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1158\/0008-5472.CAN-12-2384","article-title":"Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma","volume":"73","author":"Lyford-Pike","year":"2013","journal-title":"Cancer Res"},{"key":"2022061706052377800_bib10","doi-asserted-by":"crossref","first-page":"127ra37","DOI":"10.1126\/scitranslmed.3003689","article-title":"Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape","volume":"4","author":"Taube","year":"2012","journal-title":"Sci Transl Med"},{"key":"2022061706052377800_bib11","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-16-1821","article-title":"PD-L1 expression in melanoma: a quantitative immunohistochemical antibody comparison","author":"Sunshine","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2022061706052377800_bib12","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1097\/JTO.0000000000000687","article-title":"Expression of PD-1 and its ligands, PD-L1 and PD-L2, in smokers and never smokers with KRAS-mutant lung cancer","volume":"10","author":"Calles","year":"2015","journal-title":"J Thorac Oncol"},{"key":"2022061706052377800_bib13","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1182\/blood-2013-08-523001","article-title":"Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion","volume":"123","author":"Bachireddy","year":"2014","journal-title":"Blood"},{"key":"2022061706052377800_bib14","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.1158\/1078-0432.CCR-04-0428","article-title":"B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression","volume":"10","author":"Konishi","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2022061706052377800_bib15","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1007\/s12032-010-9515-2","article-title":"High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation","volume":"28","author":"Mu","year":"2011","journal-title":"Med Oncol"},{"key":"2022061706052377800_bib16","doi-asserted-by":"crossref","first-page":"e65821","DOI":"10.1371\/journal.pone.0065821","article-title":"PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer","volume":"8","author":"Song","year":"2013","journal-title":"PLoS One"},{"key":"2022061706052377800_bib17","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1158\/1078-0432.CCR-15-1543","article-title":"Evaluation of PD-L1 expression and associated tumor-infiltrating lymphocytes in laryngeal squamous cell carcinoma","volume":"22","author":"Vassilakopoulou","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2022061706052377800_bib18","doi-asserted-by":"crossref","first-page":"6341","DOI":"10.1158\/1078-0432.CCR-09-1652","article-title":"Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma","volume":"15","author":"Karim","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2022061706052377800_bib19","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"2022061706052377800_bib20","first-page":"p 3001","article-title":"Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature","author":"Ribas A","year":"2015"},{"key":"2022061706052377800_bib21","doi-asserted-by":"crossref","first-page":"10582","DOI":"10.1038\/ncomms10582","article-title":"Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1\/PD-L1 therapy","volume":"7","author":"Johnson","year":"2016","journal-title":"Nat Commun"},{"key":"2022061706052377800_bib22","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Eng J Med"},{"key":"2022061706052377800_bib23","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy","volume":"20","author":"Taube","year":"2014","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/77\/22\/6365\/2758172\/6365.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/77\/22\/6365\/2758172\/6365.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T13:28:33Z","timestamp":1655472513000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/77\/22\/6365\/623165\/PD-1-Expression-in-Head-and-Neck-Squamous-Cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,14]]},"references-count":23,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2017,11,14]]},"published-print":{"date-parts":[[2017,11,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-16-3453","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.22414184.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6508904.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6508904","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22414172","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22414181.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22414181","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22414169.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22414166.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22414163.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22414172.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22414169","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22414178","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22414166","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22414163","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22414184","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22414178.v1","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,14]]}}}